We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Oncolytics Meets Primary Endpoint for First Stage of U.S. Phase 2 Metastatic Melanoma Trial

News   May 27, 2013

 
Oncolytics Meets Primary Endpoint for First Stage of U.S. Phase 2 Metastatic Melanoma Trial
 
 
 

RELATED ARTICLES

Discontinuing Oral Immunotherapy for Peanut Allergy Reduces Its Protective Effects

News

A study has followed participants after oral immunotherapy (OIT) for peanut allergy have found that discontinuing OIT or continuing OIT at a reduced dose led to a decline in its protective effects.

READ MORE

“Lazy” Cancer Cells Choose the Path of Least Resistance

News

Whilst cancer cells move quickly in metastasis, they are rather lazy in which paths they choose, suggests new study.

READ MORE

Targeting Cancer's Diversity and Evolution

News

Scientists have uncovered close-up details of a vital molecule involved in the mix and match of genetic information within cells. This new information could be used to target proteins of this family to combat cancer's diversity and evolution.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE